circle

INVESTORS & MEDIA

INVESTOR OVERVIEW

  • Webcast
    X Cantor Fitzgerald Virtual Global Healthcare Conference
    Sep 16, 2020 10:00 AM EDT

    Cantor Fitzgerald Virtual Global Healthcare Conference
    Sep 16, 2020 10:00 AM EDT
  • Webcast
    X H.C. Wainwright 22nd Annual Virtual Global Investment Conference
    Sep 15, 2020 11:00 AM EDT

    H.C. Wainwright 22nd Annual Virtual Global Investment Conference
    Sep 15, 2020 11:00 AM EDT
  • Webcast
    X Morgan Stanley 18th Annual Virtual Global Healthcare Conference
    Sep 14, 2020 10:30 AM EDT

    Morgan Stanley 18th Annual Virtual Global Healthcare Conference
    Sep 14, 2020 10:30 AM EDT

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and best-in-class muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. Cytokinetics is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. More >>

ANNUAL REPORT

CORPORATE PRESENTATION

CYTOKINETICS FACT SHEETS

fact1

Company

09/21/18
( FY )
ALS

ALS

03/11/18
( FY )
SMA

SMA

07/13/18
( FY )

NEWS

Date Title and Summary
Toggle Summary Cytokinetics Announces Data to Be Presented at the HFSA Virtual Annual Scientific Meeting 2020
SOUTH SAN FRANCISCO, Calif. , Sept. 24, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that new data will be presented at the Heart Failure Society of America (HFSA) Virtual Annual Scientific Meeting 2020 taking place online from September 30, 2020 – October 6,
Toggle Summary Cytokinetics Announces Third Annual Communications Fellowship Program Call for Proposals
Grant s   Suppor t   Community Engagement for   Patient Advocacy Organization s   Focused on Cardiovascular and   Neuromuscular Diseases Deadline for Applications is November 1 3 th , 2020 SOUTH SAN FRANCISCO, Calif. , Sept. 24, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK)
Toggle Summary Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-3772271
Company Advances Second Cardiac Myosin Inhibitor SOUTH SAN FRANCISCO, Calif. , Sept. 23, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first participants have been dosed in a Phase 1 placebo-controlled, single ascending dose clinical study of CK-3772271
Toggle Summary Cytokinetics Announces GALACTIC-HF Accepted for Presentation In Late Breaking Clinical Trial Session At American Heart Association Scientific Sessions
Trial Proceeding Toward Conclusion, Topline Results Expected in Q4 2020 SOUTH SAN FRANCISCO, Calif. , Sept. 17, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that GALACTIC-HF ( G lobal A pproach to L owering A dverse C ardiac Outcomes T hrough I mproving C

EVENTS

There are currently no events to display.